Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis

American Journal of Hypertension

Volumn 20, Issue 3, 2007, Pages 233-241

  Palmas, Walter ^a   Ma, Shuangge ^b   Psaty, Bruce ^c   Goff Jr , David C ^d   Darwin, Christine ^e   Barr, R Graham ^a  

^a Mailman School of Public Health ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antihypertensive drugs; atherosclerosis; C Reactive protein; cytokines; inflammation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AFRICAN AMERICAN; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ETHNICITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; UNITED STATES;

EID: 33847115692     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.08.006     Document Type: Article

References (33)

1. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
2. Bautista L.E., Atwood J.E., O'Malley P.G., and Taylor A.J. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 15 (2004) 331-336
3. Yasunari K., Maeda K., Watanabe T., Nakamura M., Yoshikawa J., and Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 43 (2004) 2116-2123
4. Schieffer B., Bunte C., Witte J., Hoeper K., Boger R.H., Schwedhelm E., and Drexler H. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
5. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
6. Rosei E.A., Rizzoni D., Muiesan M.L., Sleiman I., Salvetti M., Monteduro C., and Porteri E. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 23 (2005) 435-444
7. Pahor M., Franse L.V., Deitcher S.R., Cushman W.C., Johnson K.C., Shorr R.I., Kottke-Marchant K., Tracy R.P., Somes G.W., and Applegate W.B. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 105 (2002) 457-461
8. Amar J., Ruidavets J.B., Peyrieux J.C., Mallion J.M., Ferrieres J., Safar M.E., and Chamontin B. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension 46 (2005) 151-155
9. Bild D.E., Bluemke D.A., Burke G.L., Detrano R., Diez Roux A.V., Folsom A.R., Greenland P., Jacob Jr. D.R., Kronmal R., Liu K., Nelson J.C., O'Leary D., Saad M.F., Shea S., Szklo M., and Tracy R.P. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156 (2002) 871-881
10. Psaty B.M., Lee M., Savage P.J., Rutan G.H., German P.S., Lyles M., and The Cardiovascular Health Study Collaborative Research Group. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. J Clin Epidemiol 45 (1992) 683-692
11. Vitelli L.L., Crow R.S., Shahar E., Hutchinson R.G., Rautaharju P.M., Folsom A.R., and Atherosclerosis Risk in Communities (ARIC) Study Investigators. Electrocardiographic findings in a healthy biracial population. Am J Cardiol 81 (1998) 453-459
12. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
13. Jenkins N.P., Keevil B.G., Hutchinson I.V., and Brooks N.H. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 112 (2002) 269-274
14. Doo Y.C., Kim D.M., Oh D.J., Ryu K.H., Rhim C.Y., and Lee Y. Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris. Am J Cardiol 88 (2001) 422-424
15. Anzai T., Yoshikawa T., Takahashi T., Maekawa Y., Okabe T., Asakura Y., Satoh T., Mitamura H., and Ogawa S. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99 (2003) 47-53
16. Elenkov I.J., Wilder R.L., Chrousos G.P., and Vizi E.S. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52 (2000) 595-638
17. Takeda T., Hoshida S., Nishino M., Tanouchi J., Otsu K., and Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169 (2003) 155-158
18. Brull D.J., Sanders J., Rumley A., Lowe G.D., Humphries S.E., and Montgomery H.E. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 87 (2002) 252-255
19. Joynt K.E., Gattis W.A., Hasselblad V., Fuzaylov S.Y., Serebruany V.L., Gurbel P.A., Gaulden L.H., Felker G.M., Whellan D.J., and O'Connor C.M. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 93 (2004) 783-785
20. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
21. Douglas J.G. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs 5 (2005) 1-6
22. Lakoski S.G., Herrington D.M., Siscovick D.M., and Hulley S.B. C-Reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 166 (2006) 345-349
23. Ferdinand K.C. Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens 16 (2003) 50S-54S
24. Kalus J.S., and Nappi J.M. Role of race in the pharmacotherapy of heart failure. Ann Pharmacother 36 (2002) 471-478
25. Padilla P.I., Chang M.J., Pacheco-Rodriguez G., Adamik R., Moss J., and Vaughan M. Interaction of FK506-binding protein 13 with brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1): effects of FK506. Proc Natl Acad Sci USA 100 (2003) 2322-2327
26. Fansa I., Gol M., Nisanoglu V., Yavas S., Iscan Z., and Tasdemir O. Does diltiazem inhibit the inflammatory response in cardiopulmonary bypass?. Med Sci Monit 9 (2003) PI30-PI36
27. Laragh J.H. Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens 14 (2001) 1173-1177
28. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
29. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
30. Ohsawa M., Okayama A., Nakamura M., Onoda T., Kato K., Itai K., Yoshida Y., Ogawa A., Kawamura K., and Hiramori K. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 41 (2005) 651-656
31. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F., Phillips R.A., Raskin P., Wright Jr. J.T., Waterhouse B., Lukas M.A., Anderson K.M., and Bell D.S. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46 (2005) 1309-1315
32. Phizackerley D.G. ASCOT: a tale of two treatment regimens: don't lose your head over ASCOT. BMJ 331 (2005) 1022
33. Psaty B.M., Koepsell T.D., Lin D., Weiss N.S., Siscovick D.S., Rosendaal F.R., Pahor M., and Furberg C.D. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47 (1999) 749-754